Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px
Document › Details

Genedata AG. (2/7/13). "Press Release: Ono Pharmaceutical Selects Genedata Expressionist for Mass Spectrometry". Basel & Tokyo.

Organisations Organisation Genedata AG
  Group Genedata (Group)
  Organisation 2 Ono Pharmaceutical Co., Ltd. (TSE: 4528)
  Group Ono Pharmaceutical (Group)
Products Product Genedata Expressionist for Mass Spectrometry (s/w)
  Product 2 multiple reaction monitoring (MRM) technology
Index term Index term Ono Pharmaceutical–Genedata: mass spectrometry s/w, 201302– license to Genedata Expressionist for Mass Spectrometry
Persons Person Pfannes, Othmar (Genedata 200406 CEO)
  Person 2 Kurz, Allison (Genedata 201004 Marketing & Communication)
     


Global leader in drug discovery advances targeted proteomics and metabolomics with extended use of Genedata Expressionist®


Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that ONO PHARMACEUTICAL CO., LTD. (ONO) extended its Genedata collaboration with a license of Genedata Expressionist for Mass Spectrometry. ONO is a leading R&D-oriented international pharmaceutical company, which provides treatments for oncological and cardiovascular diseases. The Genedata Expressionist system, an enterprise and comprehensive platform for omics data management, will be used by ONO to further strengthen its targeted proteomics and metabolomics research.

"Our daily research demands accurate mass profiling analysis as well as powerful MRM capabilities for effective quantitative analysis," noted Director of Tsukuba Research Institute at ONO. "Genedata Expressionist for Mass Spectrometry supports our proteomics and metabolomics research with a sophisticated data analysis platform that can process chromatograms ranging from 2MB to over 1GB. And, the system's ability to integrate data from a variety of instruments is a valuable benefit to us. Finally, with Genedata Expressionist we can rely on superior algorithms that generate clinically relevant biomarkers supporting efficient research processes."

Experimental designs of molecular profiling studies in the life sciences are continually growing in complexity and size. Genedata Expressionist analyzes and manages genomic, transcriptomic, proteomics, metabolomics, and epigenomic data from leading technologies including next-generation sequencing, high-density microarrays, RT-PCR, and other genomic tools. Additionally, Genedata Expressionist enables integrated analysis and management of all major mass spectrometry (MS) profiling applications including a comprehensive solution for proteomic, metabolomic, and lipidomic data from all major MS technologies.

With robust support of MRM data, the system's innovative capabilities include:

> Data Visualization

> Background Subtraction

> Grid Alignment

> Peak Detection

> Annotation

"We are proud of our collaboration with ONO, one of the world's leading pharmaceutical companies providing innovative drug therapies," said Dr. Othmar Pfannes, CEO of Genedata. "With Genedata Expressionist and its support of innovative technologies such as MS and next-generation sequencing, we provide an integrative computational platform that supports customers such as ONO who are pioneering novel therapies. And, we are committed to continuous innovation by expanding the scope Genedata Expressionist applications in areas such as molecular diagnostics and personalized healthcare."


About Genedata

Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. www.genedata.com.


Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Press Contacts
Allison Kurz
Marketing & Communications
+41 61 511 8459
communications genedata.com

Jackie Thrasivoulos
Public Relations
+1 508 881 3109
jackie.thrasivoulos genedata.com

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Genedata (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px




» top